Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group.

Diabetes Care. 2011 Nov;34(11):2403-5. doi: 10.2337/dc11-1248. Epub 2011 Sep 20.

2.

Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study.

Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB.

Diabetes Technol Ther. 2012 Jul;14(7):644-7. doi: 10.1089/dia.2011.0294. Epub 2012 Apr 23.

3.

Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.

Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV.

Pediatr Diabetes. 2012 Feb;13(1):6-11. doi: 10.1111/j.1399-5448.2011.00793.x. Epub 2011 Jul 3.

PMID:
21722284
4.

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience.

Buse JB, Dailey G, Ahmann AA, Bergenstal RM, Green JB, Peoples T, Tanenberg RJ, Yang Q.

Diabetes Technol Ther. 2011 Jun;13(6):601-6. doi: 10.1089/dia.2010.0225. Epub 2011 Apr 13.

5.

Patient behaviors associated with optimum glycemic outcomes with sensor-augmented pump therapy: insights from the STAR 3 study.

Tanenberg RJ, Welsh JB.

Endocr Pract. 2015 Jan;21(1):41-5. doi: 10.4158/EP14187.OR.

PMID:
25100386
6.

Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.

Hirsch IB, Abelseth J, Bode BW, Fischer JS, Kaufman FR, Mastrototaro J, Parkin CG, Wolpert HA, Buckingham BA.

Diabetes Technol Ther. 2008 Oct;10(5):377-83. doi: 10.1089/dia.2008.0068.

PMID:
18715214
7.

Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study.

Rosenlund S, Hansen TW, Rossing P, Andersen S.

J Clin Endocrinol Metab. 2015 Nov;100(11):4181-8. doi: 10.1210/jc.2015-2839. Epub 2015 Sep 21.

PMID:
26390102
8.

Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial.

Perkins BA, Halpern EM, Orszag A, Weisman A, Houlden RL, Bergenstal RM, Joyce C.

Can J Diabetes. 2015 Feb;39(1):50-4. doi: 10.1016/j.jcjd.2014.03.003. Epub 2014 Aug 29.

PMID:
25175313
9.

Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M.

Diabetes Care. 2009 Dec;32(12):2245-50. doi: 10.2337/dc09-0750. Epub 2009 Sep 18.

10.
11.
12.

Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.

Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, DeVries JH.

Diabet Med. 2011 Oct;28(10):1158-67. doi: 10.1111/j.1464-5491.2011.03256.x.

PMID:
21294770
13.

2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.

Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L; AP@home consortium.

Lancet Diabetes Endocrinol. 2015 Dec;3(12):939-47. doi: 10.1016/S2213-8587(15)00335-6. Epub 2015 Sep 30.

PMID:
26432775
14.

Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study.

Nørgaard K, Scaramuzza A, Bratina N, Lalić NM, Jarosz-Chobot P, Kocsis G, Jasinskiene E, De Block C, Carrette O, Castañeda J, Cohen O; Interpret Study Group.

Diabetes Technol Ther. 2013 Apr;15(4):273-80. doi: 10.1089/dia.2012.0288. Epub 2013 Feb 25.

15.

Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children.

Zucchini S, Scipione M, Balsamo C, Maltoni G, Rollo A, Molinari E, Mangoni L, Cicognani A.

Diabetes Technol Ther. 2011 Dec;13(12):1187-93. doi: 10.1089/dia.2011.0080. Epub 2011 Aug 19.

PMID:
21854193
16.

Treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial.

Peyrot M, Rubin RR; STAR 3 Study Group.

Diabet Med. 2013 Apr;30(4):464-7. doi: 10.1111/dme.12079.

PMID:
23496302
18.

Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.

Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B.

Diabetes Care. 2004 Nov;27(11):2590-6.

PMID:
15504991
19.

Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.

Picard S, Hanaire H, Baillot-Rudoni S, Gilbert-Bonnemaison E, Not D, Reznik Y, Guerci B.

Diabetes Technol Ther. 2016 Mar;18(3):127-35. doi: 10.1089/dia.2015.0240. Epub 2016 Mar 7.

PMID:
26950530
20.

Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.

Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH.

Ann Intern Med. 2012 Sep 4;157(5):336-47. Review.

PMID:
22777524

Supplemental Content

Support Center